JPRN-jRCT2080223065未知2 期
A Multi-Center, Randomized, Double-Blind, Placebo- Controlled Study to Investigate the Efficacy and Safety of 52 Weeks Treatment With QGE031 s.c. in Asthma Patients Not Adequately Controlled by Medium- or High-dose ICS Plus LABA With or Without OCS
ovartis Pharma K.K.0 个研究点目标入组 50 人开始时间: 2016年1月7日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •*A diagnosis of allergic asthma, uncontrolled on current medication
- •*History of at least 2 asthma exacerbations during the last 1 year
- •*Forced Expiratory Volume in one second (FEV1) of >= 40% and <= 80% of the predicted normal value; reversibility following administration of bronchodilator
排除标准
- •*Use of tobacco products within the previous 6 months (Social occasional smokers may be included).
- •*Recent asthma attack/exacerbation or asthma worsening/ respiratory infection.
- •Other protocol defined inclusion/exclusion may apply
研究者
相似试验
进行中（未招募）
1 期
Efficacy, Safety, and Durability of Response of BMS-986165 versus Placebo and Active Comparator in Subjects with PsoriasisModerate-to-Severe Plaque PsoriasisMedDRA version: 20.0Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 100000004858EUCTR2018-001925-24-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO1,000
进行中（未招募）
不适用
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group StudyComparing SYR-322 Alone and Combination SYR-322 with Pioglitazone versus Placebo on Postprandial Lipids in Subjects with Type 2 Diabetes - Post-PrandialType 2 diabetes mellitusMedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2007-000486-38-SETakeda Global Research & Development Centre (Europe) Ltd.,71
未知
2 期
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe PsoriasisPsoriasisJPRN-jRCT2080223467Bristol-Myers Squibb K.K.250
进行中（未招募）
不适用
Efficacy and safety of QGE031 versus placebo in patients aged 18-75 years with asthma not adequately controlled with standard of care medication (inhaled corticosteroids plus long lasting beta agonists with or without oral corticosteroids)Severe AsthmaMedDRA version: 18.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2014-003155-57-DEovartis Pharma Services AG440
进行中（未招募）
1 期
Efficacy, Safety, and Durability of Response of BMS-986165 versus Placebo and Active Comparator in Subjects with PsoriasisEUCTR2018-001925-24-FIBristol-Myers Squibb International Corporation1,000